• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Experts Define Visual Fatigue as Distinct Functional Disease

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Experts Define Visual Fatigue as Distinct Functional Disease

Experts Define Visual Fatigue as Distinct Functional Disease

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An international panel of experts has reached a formal consensus defining visual fatigue as a distinct functional disease, establishing standardized diagnostic criteria and core symptoms to address the condition’s growing global burden. Published in Ophthalmology and Therapy, the study utilized a modified Delphi process to harmonize previously inconsistent definitions, assessment methods, and management principles for a condition that affects individuals of all ages worldwide. The initiative, supported by the Asia–Pacific Association of Visual Fatigue, aims to provide a foundational framework for clinical and epidemiologic practice, moving beyond the fragmented approach that has characterized the field for years.

The research team addressed a significant gap in ophthalmic care where universally accepted definitions and standardized diagnostic criteria remained lacking. Visual fatigue, also known as asthenopia, digital eye strain, or computer vision syndrome, is commonly characterized by visual symptoms associated with prolonged visual tasks. However, epidemiological studies have reported widely varying prevalence rates, ranging from 36 to 90%, largely due to inconsistencies in diagnostic criteria and study populations. This heterogeneity complicates both clinical assessment and research design, as there was no prior consensus on which symptoms are essential for diagnosis or intervention.

To resolve these issues, the researchers conducted a modified Delphi study with an international panel of experts in optometry, ophthalmology, and related disciplines. Out of 20 experts invited, 14 participated in the panel, representing a 70% response rate. Thirteen experts completed the second-round questionnaire, and 12 participated in a subsequent hybrid meeting that combined in-person and online discussions. This methodology allowed the panel to combine evidence-based data from a recent systematic review with expert opinion, ensuring that the final recommendations were grounded in current literature while reflecting collective clinical experience.

The consensus resulted in three major recommendations comprising 13 constituent items. The first recommendation defines visual fatigue as a functional disease characterized by a core symptom set and functional impact. The panel specified that visual fatigue is a functional disease characterized by one or more core ocular symptoms, including eye strain, difficulty focusing at near, having to strain to see well, and task-related headache, that emerge and worsen during sustained visual activities. This definition distinguishes visual fatigue from other conditions by emphasizing the temporal link between sustained visual tasks and symptom onset, a fundamental aspect of the diagnosis.

A critical decision by the panel was to differentiate visual fatigue from dry eye disease (DED). Although DED frequently coexists with visual fatigue, the two conditions exhibit distinct clinical profiles, such as differences in tear film break-up time, screen time, age distribution, and symptom severity. Consequently, symptoms highly specific to ocular surface irritation, such as burning, itching, and eye dryness, were excluded from the core definition of visual fatigue. Instead, the panel identified eye discomfort and heavy eyelids as supportive but non-core symptoms. This distinction preserves diagnostic clarity while acknowledging that a diagnosis of visual fatigue remains valid alongside concurrent DED, which should be managed concurrently as part of an individualized treatment plan.

The second recommendation specifies a structured assessment pathway for clinicians. The panel suggested that minimum examinations should include visual acuity, refraction, ocular surface evaluation, and assessment of binocular and accommodative functions. Ocular surface evaluation is conducted as part of comorbidity identification rather than as a direct measure of visual fatigue. The panel also endorsed the use of subjective questionnaires, recommending the Computer Vision Syndrome Questionnaire (CVS-Q) as an interim screening tool due to its broad applicability. The Asthenopia Symptoms Questionnaire (ASQ-11) was endorsed for general screening, while the Convergence Insufficiency Symptom Survey (CISS) is specifically recommended to evaluate reading-related symptoms. These tools are considered supportive rather than definitive, pending the development of a brief, standardized questionnaire that captures task-related worsening and functional impact.

Objective assessments play a complementary role in the diagnostic framework, particularly in research or specialized settings. The panel highlighted emerging technologies that can detect physiological signs of fatigue before subjective symptoms become severe. Key metrics include eye tracking parameters such as fixation stability and blink metrics, critical flicker fusion frequency, and accommodative microfluctuations. These objective measures may serve as indicators of ciliary muscle stress and central nervous system fatigue. However, the panel noted that current objective tools lack universal cutoffs and normative data, limiting their widespread use in routine clinical practice. The consensus aims to encourage the generation of normative data for these tools to support their eventual translation from research to clinical care.

The diagnostic framework proposed by the panel requires that four out of five criteria be met to diagnose visual fatigue. These criteria include the occurrence or worsening of at least one core symptom during sustained visual tasks, symptoms triggered and recurring with similar tasks, objective assessment showing relevant abnormalities, the presence of functional impact, and the assessment and addressing of key comorbid conditions. Including functional impact ensures that treatment is prioritized for individuals whose daily activities or work performance are significantly compromised. This approach distinguishes clinically significant visual fatigue from transient, non-pathological eye strain, which might not warrant aggressive intervention.

The third recommendation focuses on prioritizing high-risk populations and addressing modifiable risk factors. The panel identified visually intensive workers, such as IT professionals, students with prolonged screen exposure, and children with refractive error as groups most susceptible to visual fatigue. Risk factors to prioritize include uncorrected refractive error, prolonged screen time, lack of regular breaks during screen use, suboptimal ambient conditions, short or poor-quality sleep, control of prior eye disease, and contact lens wear practices. These modifiable risk factors were endorsed by more than 70% of the panelists, reflecting strong consensus on their importance in the development and management of visual fatigue.

Management principles adopted by the panel follow a stepwise approach starting with refractive correction and environmental modifications. The recommended steps include correcting refractive error, scheduling regular breaks such as the 20-20-20 rule, improving sleep quality, and optimizing ambient conditions including humidity, glare control, illumination, and ergonomics. Clinicians are also advised to identify and address binocular or accommodative anomalies and manage coexisting dry eye separately. This holistic approach ensures that all potential contributors to visual fatigue are identified and managed in parallel to maximize the alleviation of symptoms.

The study acknowledges several limitations, primarily the reliance on subjective expert opinion inherent in the Delphi method. The hybrid meeting format compromised the strict anonymity of a traditional Delphi process, potentially introducing conformity bias where decisions could be influenced by dominant voices. Additionally, the participants were predominantly from the Asia–Pacific region, which may limit the generalizability of the consensus across different global populations and healthcare systems. Not all relevant clinical perspectives, such as neuro-ophthalmologists or occupational health specialists, were comprehensively represented, highlighting the need for broader, globally inclusive discussions in the future.

Despite these limitations, the consensus provides a crucial step in addressing the global burden of visual fatigue. By redefining visual fatigue as a distinct functional disease, the panel offers a clear definition and a core symptom set for clinical practice. The structured framework for diagnosis and assessment emphasizes evaluating functional impact and co-managing comorbidities, particularly dry eye disease. While accessible objective assessment tools and specific therapeutic interventions still need validation, this consensus initiates future global, multidisciplinary research aimed at improving the standard of care for visual fatigue.

Beyond core definitions, the consensus clarifies diagnostic recall windows and addresses current disease classifications. In existing coding systems, such as ICD-11, asthenopia is categorized under visual discomfort as a subjective visual experience that cannot be verified objectively, while ICD-10 lacks an independent definition. To capture clinical progression accurately, the panel recommended a standard one-month recall period for general reporting, aligning with recommendations from the FDA for patient-reported outcome measures. However, clinicians may shorten this reporting window to two weeks when patients present with acute functional impairment, such as substantial drops in daily productivity or mental distress, while epidemiological studies should maintain the uniform one-month window for data comparability.

The expert panel also highlighted distinctive diagnostic challenges in pediatric populations, where young children often lack the self-awareness or vocabulary to describe visual symptoms accurately. In these young patients, clinicians are advised to monitor surrogate behavioral indicators during reading or display screen tasks, such as frequent eye rubbing, excessive blinking, abnormal head posturing, and holding visual material at an unusually close working distance. Alongside behavioral checklists, gathering objective markers like reading speed, oculomotor parameters, and accommodative microfluctuations can help bridge critical diagnostic gaps in pediatric care.

Regarding broader clinical translation, the authors emphasized structural barriers that currently hinder the adoption of objective tools. Advanced assessments such as critical flicker fusion frequency and eye-tracking lack standardized diagnostic cutoffs, and clinicians face reimbursement hurdles due to an absence of designated billing codes. Panelists from regions including Australia noted that specialized testing equipment remains predominantly confined to academic laboratories or specialty clinics rather than primary optometric practices. To establish a stronger evidence base, the panel advised tracking tangible functional outcomes across future trials and routine practice, specifically monitoring school and work productivity, reading speed, mental health indicators including anxiety and stress, and musculoskeletal symptoms like neck and shoulder pain.

Subject of Research: Consensus on Diagnostic Criteria, Clinical Symptoms, and Risk Factors for Visual Fatigue: A Modified Delphi Study

Article Title: Consensus on Diagnostic Criteria, Clinical Symptoms, and Risk Factors for Visual Fatigue: A Modified Delphi Study

Article References: Chen, Y., Liu, Z., Song, F., Tong, L., Wu, C. Y., Liang, L., Jie, Y., Tsubota, K., Hori, Y., Kee, C.-S., Zhou, L., Seo, K. Y., Young, A., Congdon, N., Gong, X., & He, M. (2026). Consensus on Diagnostic Criteria, Clinical Symptoms, and Risk Factors for Visual Fatigue: A Modified Delphi Study. Ophthalmology and Therapy, 15(11), 3625-3641. https://doi.org/10.1007/s40123-026-01491-1

Image Credits: AI Generated

DOI: 10.1007/s40123-026-01491-1

Keywords: Consensus, Diagnostic, Criteria, Clinical, Symptoms, Risk, Factors, Visual, Fatigue, Modified, Delphi

News Source: Ophelia Keating. (November 20, 2026). Experts Define Visual Fatigue as Distinct Functional Disease. Scienmag.

Tags: ClinicalconsensuscriteriaDelphiDiagnosticfactorsfatiguemodifiedrisksymptomsvisual
Share12Tweet7Share2ShareShareShare1

Related Posts

Severe COVID-19 Alters Hepatic Autophagy Markers Despite Absent Hepatocyte ACE2 Receptors

Severe COVID-19 Alters Hepatic Autophagy Markers Despite Absent Hepatocyte ACE2 Receptors

November 20, 2026
Review Finds Limited Evidence That Decontamination Restores Bone-to-Implant Contact

Review Finds Limited Evidence That Decontamination Restores Bone-to-Implant Contact

November 20, 2026

Computational Screening and Cell Tests Link Rhodiola Compound to Lung Cancer Suppression

November 20, 2026

Bivalent RSVpreF Vaccine Protects Older Adults Against Severe Disease Across Three Seasons

November 20, 2026

POPULAR NEWS

  • Astrocytic GFAP Upregulation Reduces Tau Pathology in Mouse Model of Tauopathy

    Astrocytic GFAP Upregulation Reduces Tau Pathology in Mouse Model of Tauopathy

    29 shares
    Share 12 Tweet 7
  • Acidic Ponds Link to Lower Pathogen Prevalence in Palmate Newts

    29 shares
    Share 12 Tweet 7
  • Early YAP and Beta-Catenin Signaling Links Stomach Infection to Liver Colonization

    29 shares
    Share 12 Tweet 7
  • Cold Storage Preserves Peach Firmness by Triggering RNA Degradation of Expansin Transcripts

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Y-Chromosome Markers Reveal High Diversity and Shared Paternal Ancestry in Western Iranian Kurds

Severe COVID-19 Alters Hepatic Autophagy Markers Despite Absent Hepatocyte ACE2 Receptors

Review Finds Limited Evidence That Decontamination Restores Bone-to-Implant Contact

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.